Cargando…

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes

Type 1 diabetes mellitus (T1DM) with obesity is increasingly common, prompting effective clinical interventions to induce weight loss in this population. We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide. Case 1: A 32-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Gunther, Garner, Erica M, Srivastava, Gitanjali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580416/ https://www.ncbi.nlm.nih.gov/pubmed/37908483 http://dx.doi.org/10.1210/jcemcr/luad040

Ejemplares similares

Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
por: Liberini, Claudia G., et al.
Publicado: (2019)

GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Combination anti‐obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center
por: Wong, Gunther, et al.
Publicado: (2022)

Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
por: Boyle, Christina Neuner, et al.
Publicado: (2017)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
por: Tufvesson-Alm, Maximilian, et al.
Publicado: (2023)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Acquired Brain Injury-Induced Hyperphagia and Obesity, Successfully Treated With a GLP-1 Agonist
por: Ngu, Michael, et al.
Publicado: (2021)

Amylin as a Future Obesity Treatment
por: Dehestani, Babak, et al.
Publicado: (2021)

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
por: Safaeian, Leila, et al.
Publicado: (2020)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Thermodynamic surprises of Cu(II)–amylin analogue complexes in membrane mimicking solutions
por: Dzień, Emilia, et al.
Publicado: (2022)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
por: Srivastava, Gitanjali, et al.
Publicado: (2019)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

The effects of GLP-1 analogues on pre-diabetes of the children
por: Zhou, Qing-Xia, et al.
Publicado: (2017)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Amylin in the Periphery
por: Wookey, Peter J., et al.
Publicado: (2003)

Combination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
por: Duca, Frank A., et al.
Publicado: (2013)

Amylin Analogues in the Treatment of Diabetes Mellitus: Medicinal Chemistry and Structural Basis of its Function
por: Adeghate, Ernest, et al.
Publicado: (2011)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
por: Sonne, Nina, et al.
Publicado: (2020)

The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy
por: Sonne, Nina, et al.
Publicado: (2022)

Correlation of leptin, neuropeptide Y and amylin in childhood obesity
por: Kim, Eun Young, et al.
Publicado: (2013)

Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model
por: Katri, Anna, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
por: Wagner, Stefan, et al.
Publicado: (2022)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
por: de Boer, Stefanie Amarens, et al.
Publicado: (2015)

An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder
por: Kalafateli, Aimilia Lydia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hpujf89cg2d37aupnafg8qeldd